Adjunctive Effects of A Piscean Collagen-Based Controlled-Release Chlorhexidine Chip in the Treatment of Chronic Periodontitis: A Clinical and Microbiological Study

John, Priya M.; Lazarus, Flemingson; George, Joann Pauline; Selvam, A.; Prabhuji, Munivenkatappa Lakshmaiah Venkatesh

doi:10.7860/jcdr/2015/11534.5965

Cited by 15 publications

(23 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the use of mammal collagen may be complicated by an allergic reaction induced in 3-4% of the population [12]. Therefore, fish collagen is being subjected to intensive research with an emphasis on its application for medical purposes [3,[13][14][15][16]. Since fish-derived collagen exhibits a lower melting temperature and less reproducible properties than mammal collagen [17], it must be crosslinked in order to obtain a product that exhibits reproducible properties [14].…”

Section: Introductionmentioning

confidence: 99%

Vancomycin-releasing cross-linked collagen sponges as wound dressings

Hartinger

Mitáš

Mlček

et al. 2019

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

The study presents a novel vancomycin-releasing collagen wound dressing derived from Cyprinus carpio collagen type I cross-linked with carbodiimide which retarded the degradation rate and increased the stability of the sponge. Following lyophilization, the dressings were subjected to gamma sterilization. The structure was evaluated via scanning electron microscopy images, micro-computed tomography, and infrared spectrometry. The structural stability and vancomycin release properties were evaluated in a phosphate buffer solution. Microbiological testing and a rat model of a wound infected with methicillin-resistant Staphylococcus aureus (MRSA) were then employed to test the efficacy of the treatment of the infected wound. Following an initial mass loss due to the release of vancomycin, the sponges remained stable. After 7 days of exposure in phosphate buffered saline (37°C), 60% of the material remained with a preserved collagen secondary structure together with a high degree of open porosity (over 80%). The analysis of the release of the vancomycin revealed the homogeneous distribution of the antibiotic both across and between the sponges. The release of vancomycin was retarded as proved by in vitro testing and further confirmed by the animal model from which measurable concentrations were observed in blood samples 24 hours after the subcutaneous implantation of the sponge, which was more than observed following i. p. administration. The sponge was also highly effective in terms of reducing the number of colony-forming units in biopsies extracted from the infected wounds 4 days following the inoculation of the wounds with the MRSA solution.

show abstract

Section: Introductionmentioning

confidence: 99%

Vancomycin-releasing cross-linked collagen sponges as wound dressings

Hartinger

Mitáš

Mlček

et al. 2019

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

show abstract

“…We combined data from 6 studies [ 22 , 23 , 25 – 27 , 29 ] to compare the GI score improvements between groups at 3-month follow-up. Figure 10 shows the forest plot with mean differences in GI score improvements between groups, suggesting that the sites treated with SRP and CHX chip had a better response than those treated with SRP alone (MD, 0.32; 95% CI, 0.15–0.48; p < 0.001).…”

Section: Resultsmentioning

confidence: 99%

Effect of chlorhexidine chip as an adjunct in non-surgical management of periodontal pockets: a meta-analysis

Diao

2020

BMC Oral Health

View full text Add to dashboard Cite

Background The aim of this meta-analysis was to evaluate the difference in treatment outcomes between sub-gingival placement of chlorhexidine chip (CHX chip) in adjunct to scaling and root planing (SRP) and SRP alone for the management of periodontal pockets in patients suffering from chronic periodontitis. Methods We searched the MEDLINE (PubMed), SCOPUS and CENTRAL databases and identified 15 randomized clinical trials published within the last decade (2007–2019): 9 with split-mouth design and 6 with parallel study design. We extracted data and performed both qualitative and quantitative syntheses. The primary outcomes assessed were gain in clinical attachment level (CAL), reduction in probing pocket depth (PPD), improvement in gingival inflammation, and results of microbiological assays. Results We used meta-analysis plots to assess all the clinical outcomes. The mean differences in PPD reductions at 1 month (MD 0.63), 3 months (MD 0.69), and 6 months (MD 0.75); and the CAL gains at 1 month (MD 0.54), 3 months (MD 0.64), and 6 months (MD 0.68) showed more favorable responses in sites treated with the CHX chip as an adjuvant to SRP, than in sites treated with SRP alone. Conclusion SRP with adjunctive CHX chips showed better clinical outcomes than SRP alone for the management of periodontal pockets in patients with chronic periodontitis.

show abstract

“…The constant outflow of the gingival crevicular fluid from the periodontal pocket (up to 40 times an hour) renders subgingival irrigation of chlorhexidine useless in delivering significant antimicrobial benefits, reduction in probing depths, and clinical attachment level gain to manage chronic periodontitis; however, the use of a collagen-based release vehicle allows for a controlled delivery of chlorhexidine to achieve the intended pharmaceutical effects. 29 Furthermore, current clinical trials are investigating cross-linked, absorbable collagen sponges as protein-carrier vehicles. Prolonged release of bioactive proteins, such as recombinant human bone morphogenic protein-2 (rhBMP-2), have been reported when utilized in conjunction with collagen matrices due to desirable interactions of the collagen matrix with the protein.…”

Section: Natural Biodegradable Polymeric Biomaterialsmentioning

confidence: 99%

Current development of biodegradable polymeric materials for biomedical applications

Song

Murphy

et al. 2018

DDDT

654

358

View full text Add to dashboard Cite

In the last half-century, the development of biodegradable polymeric materials for biomedical applications has advanced significantly. Biodegradable polymeric materials are favored in the development of therapeutic devices, including temporary implants and three-dimensional scaffolds for tissue engineering. Further advancements have occurred in the utilization of biodegradable polymeric materials for pharmacological applications such as delivery vehicles for controlled/sustained drug release. These applications require particular physicochemical, biological, and degradation properties of the materials to deliver effective therapy. As a result, a wide range of natural or synthetic polymers able to undergo hydrolytic or enzymatic degradation is being studied for biomedical applications. This review outlines the current development of biodegradable natural and synthetic polymeric materials for various biomedical applications, including tissue engineering, temporary implants, wound healing, and drug delivery.

show abstract

Adjunctive Effects of A Piscean Collagen-Based Controlled-Release Chlorhexidine Chip in the Treatment of Chronic Periodontitis: A Clinical and Microbiological Study

Cited by 15 publications

References 37 publications

Vancomycin-releasing cross-linked collagen sponges as wound dressings

Vancomycin-releasing cross-linked collagen sponges as wound dressings

Effect of chlorhexidine chip as an adjunct in non-surgical management of periodontal pockets: a meta-analysis

Current development of biodegradable polymeric materials for biomedical applications

Contact Info

Product

Resources

About